Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Phase III topline results for tanezumab in chronic low back pain

Feb. 19, 2019

Takeda Pharmaceutical identifies orexin OX2 receptor agonists

Feb. 19, 2019

Human parthenogenetic stem cell therapy improves experimental traumatic brain injury deficits

Feb. 19, 2019

Otsuka Pharmaceutical initiates two phase III trials of centanafadine in adults with ADHD

Feb. 19, 2019

Enrollment underway in phase I study of J-147

Feb. 19, 2019

Bionomics reports pharmacometric analysis of phase II RESTORE trial of BNC-210 for PTSD

Feb. 18, 2019

Lundbeck presents compounds for schizophrenia

Feb. 18, 2019

Huntingtin implicated in fragile X syndrome

Feb. 18, 2019

ApoE-complement link opens door for new targets in Alzheimer's, atherosclerosis

Feb. 15, 2019

KA-11 demonstrates promising activity in preclinical models of epilepsy and pain

Feb. 15, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 26, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 26, 2026
Dual-targeting, rapamycin-enhanced CAR T for multiple myeloma
BioWorld Science
Umoja Biopharma Inc. performed preclinical studies to evaluate the antitumor activity of UB-VV500, an off-the-shell lentiviral vector CAR T-cell product. It is...